Behavioral health company Acadia Healthcare (NASDAQ: ACHC) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 5.1% year on year to $895.3 million. The company’s full-year revenue guidance of $3.45 billion at the midpoint came in 0.6% above analysts’ consensus estimates. Its non-GAAP profit of $0.60 per share was 29.2% above analysts’ consensus estimates.

For more on Acadia Healthcare, read our free full research report.

“Acadia delivered strong results in the third quarter, and our positive momentum is driving our increased full-year guidance. We remain focused on our key priorities, including expanding access to quality patient care and consistent operational execution with financial discipline," said Debbie Osteen, Chief Executive Officer of Acadia. "We've expanded our footprint by opening 16 new acute facilities over the last four years, and based on the progress we've made so far this year, we now expect to deliver approximately $60 million of incremental EBITDA from these facilities in 2027 relative to 2026. Overall, we are confident that we have the capabilities in place to continue to drive Acadia forward and deliver additional value for our patients, our partners, and our investors.”

Revenue growth

A company’s long-term revenue performance is one signal of its overall quality. Even a poor business can perform well for one or two quarters, but a high-quality one grows for years. Over the last five years, Acadia Healthcare grew its revenue at a decent 8.6% compounded annual growth rate. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Acadia Healthcare’s recent performance shows its demand has slowed as its annualized revenue growth of 4.5% over the last two years was below its five-year trend. Revenue growth deceleration in the sector warrants caution, as it could signal changing consumer tastes aided by low switching costs.

Acadia Healthcare also reports its number of admissions, which reached 56,999 in the latest quarter. Over the last two years, Acadia Healthcare’s admissions averaged 5.1% year-on-year growth. This was in line with revenue growth, indicating that prices stayed fairly consistent.

This quarter, Acadia Healthcare reported year-on-year revenue growth of 5.1%, and its $895.3 million of revenue exceeded Wall Street’s consensus estimates by 2%.

Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months, according to S&P, similar to its two-year rate. This projection is underwhelming and suggests its newer products and services will not accelerate its top-line performance yet.

Earnings per share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth. For example, a company could inflate its revenue through excessive spending on advertising and promotions.

Acadia Healthcare’s EPS declined by 14.1% annually over the last five years while its revenue grew by 8.6%. This indicates the company became less profitable on a per-share basis as it expanded.

A closer look at Acadia Healthcare’s earnings helps explain the drivers of its performance. As noted earlier, Acadia Healthcare’s operating margin declined by 58.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but reveal less about a company’s fundamentals.

In Q3, Acadia Healthcare reported adjusted EPS of $0.60, down from $0.72 in the same quarter last year. Despite falling year on year, the result came in well above analysts’ consensus estimates. Over the next 12 months, Wall Street expects Acadia Healthcare’s full-year EPS to grow 26.6% from $1.42 to $1.80, according to S&P.

Key takeaways from Acadia Healthcare’s Q3 results

Acadia Healthcare’s full-year EPS guidance stood out, topping Wall Street’s consensus estimates by a wide margin. Quarterly EPS also beat analysts’ consensus estimates, making this a solid quarter with clear positives. Shares rose 2.6% to $33.07 immediately after the results.

Acadia Healthcare reported solid earnings, but one quarter doesn’t necessarily make the stock a buy. An investment decision should consider valuation, business quality and the latest earnings. Read more in our full research report here (it’s free).